ClinicaliQ Trial Snapshot
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen — Recruiting • Phase III • Respiratory / COPD / Asthma • NCT05624450.
- Treatment being tested: Tozorakimab (a monoclonal antibody) administered as an add-on to standard care in hospitalised patients with viral lung infection requiring supplemental oxygen, with primary outcome of preventing death or progression to invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).
- Patient eligibility overview: Hospitalised patients with confirmed viral lung infection who require supplemental oxygen but have not yet progressed to requiring IMV or ECMO at baseline.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Eligibility Snapshot
- : * Adult participants ≥ 18 years old at the time of signing the informed consent form. * Patients hospitalised with viral lung infection. * Hypoxaemia requiring treatment with supplemental O2. Hypoxaemia is defined as: SpO2 ≤ 90% OR SpO2 ≤ 92% AND one or both of the following: Radiographic infiltrates by CXR/CT compatible with viral lung infection per investigator judgement. Use of accessory muscles of respiration or RR (respiratory rate) > 22. - Patient remains hypoxaemic at randomisation requiring treatment with supplemental oxygen.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.